SBIR Phase I: Identifying Toxicity Pathways

SBIR 第一阶段：确定毒性途径

• 批准号: 0610784
• 负责人: Zheng Li
• 金额: --
• 依托单位: MetagenX
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0610784&HistoricalAwards=false
• 关键词: SBIR; Phase; Identifying; Toxicity; Pathways

This Small Business Innovative Research (SBIR) Phase I project aims to develop a technology to improve the understanding of how drugs alter cellular processes. With advance in HTP technology, profiles of gene expressions, proteins and metabolites can be acquired to help elucidate the network of pathways involved in producing a specific phenotype. The project will develop a methodology that reveals the pathways that are altered and will facilitated the selection of drug candidates with the highest efficacy and minimal toxicity.Developing new drugs has become increasingly expensive, challenging and costly, not only in term of financial resources but also in toxicity. By identifying early in the drug discovery process, candidate compound with the highest probabilities of becoming successful therapies will reduce the cost of development; with the concomitant reductions in public health care costs.

这个小企业创新研究（SBIR）第一阶段项目旨在开发一种技术，以提高对药物如何改变细胞过程的理解。随着HTP技术的进步，可以获得基因表达、蛋白质和代谢物的谱，以帮助阐明产生特定表型的途径网络。该项目将开发一种方法，揭示被改变的途径，并将促进选择具有最高功效和最小毒性的候选药物。开发新药的成本越来越高，挑战越来越大，成本越来越高，不仅在资金方面，而且在毒性方面。通过在药物发现过程的早期识别，最有可能成为成功疗法的候选化合物将降低开发成本；随之而来的是公共卫生保健费用的减少。